Clinical Trial

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-05-23
notable Trial sites expanded: 15 -> 20 locations 2026-05-23
Trial Details
NCT Number NCT06842498
Lead Sponsor Kyntra Bio
Conditions Metastatic Castration-Resistant Prostate Cancer
Enrollment 75 participants
Start Date 2026-02-22
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22